Back

Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor?

30 August 2016 (10:33 - 10:40)
Organised by:
Congress Presentation Part of: Are we ever going to get to lipid goals? Epidemiology, lipids ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Christopher Paul Cannon

Brigham and Women's Hospital, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Improvement of LDL-cholesterol goal attainment in high-risk patients in Europe and Middle East between 2008/09 and 2013/14 - Results of DYSIS and DYSIS II CHD
Doctor A. Gitt (Ludwigshafen, DE)
Abstract Slides
Presentation thumbnail
Statin use and dose by low-density lipoprotein cholesterol level in U.S. commercially insured patients with type 2 diabetes
Doctor R. Rosenson (New York City, US)
Abstract Slides
Presentation thumbnail
Do we reach the LDL-c goals in Familial hypercholesterolemiapatients under Eighteen Years Old? SAFEHEART (Spanish Familial Hypercholesterolemia Longitudinal Cohort Study) follow-up study
Doctor A. Saltijeral Cerezo (Madrid, ES)
Abstract Slides
Presentation thumbnail
Still high prevalence of persistent lipid abnormalities among patients with ACS or stable CHD despite chronic statin therapy in 2014: results of DYSIS II ACS and CHD
Doctor A. Gitt (Ludwigshafen, DE)
Abstract Slides
Presentation thumbnail
Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis
Doctor N. Wong (Irvine, US)
Abstract Slides

Access the full session

Session thumbnail
Are we ever going to get to lipid goals?

The Event

Event poster

ESC Congress 2016

30 August 2016 10:33 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources